title: Steroid-induced myopathy in patients intubated due to exacerbation of chronic obstructive pulmonary disease.
abstract: OBJECTIVE
  To determine incidence, risk factors and impact on various outcome parameters of the development of acute quadriplegic myopathy in a selected population of critically ill patients.
  
  
  METHODS
  A prospective cohort study carried out in the intensive care unit of a tertiary-level university hospital.
  
  
  METHODS
  All patients admitted due to acute exacerbation of chronic obstructive pulmonary disease who required intubation and mechanical ventilation, and received high doses of intravenous corticosteroids.
  
  
  METHODS
  A neurophysiological study was performed in all cases at the onset of weaning. Muscular biopsy was taken when the neurophysiological study revealed a myopathic pattern.
  
  
  RESULTS
  Twenty-six patients were enrolled in the study. Nine patients (34.6%) developed myopathy. Only seven patients were treated with muscle relaxants. Histology confirmed the diagnosis in the three patients who underwent muscle biopsy. APACHE II score at admission, the rate of sepsis and the total doses of corticosteroids were significantly higher in patients with myopathy compared with those patients that did not develop it. Myopathy is associated with an increase in the duration of mechanical ventilation [15.4 (9.2) versus 5.7 (3.9) days; p<0.006], the length of ICU stay [23.6 (10.7) versus 11.4 (7.05) days; p<0.003] and hospital stay [33.3 (19.2) versus 21.2 (16.1) days; p<0.034)]. Myopathy was not associated with increased mortality.
  
  
  CONCLUSIONS
  In the population under study, severity of illness at admission, the development of sepsis and the total dose of corticosteroids are factors associated with the occurrence of myopathy after the administration of corticosteroids. Myopathy was associated with prolonged mechanical ventilation and in-hospital stay.
authors.affiliation: Intensive Care Unit, University Hospital Virgen del Rocío, Avenida Manuel Siurot s/n, 41013 Seville, Spain. ramaya@supercable.es
authors.forename: Rosario
authors.initials: R
authors.lastname: Amaya-Villar
authors.forename: Jose
authors.initials: J
authors.lastname: Garnacho-Montero
authors.forename: Jose Luis
authors.initials: JL
authors.lastname: García-Garmendía
authors.forename: Juan
authors.initials: J
authors.lastname: Madrazo-Osuna
authors.forename: M Carmen
authors.initials: MC
authors.lastname: Garnacho-Montero
authors.forename: Rafael
authors.initials: R
authors.lastname: Luque
authors.forename: Carlos
authors.initials: C
authors.lastname: Ortiz-Leyba
mesh_terms: D018806:APACHE; D000305:Adrenal Cortex Hormones / Q000009:adverse effects / Q000627:therapeutic use*; D000368:Aged; D017052:Hospital Mortality; D006801:Humans; D007362:Intensive Care Units; D007902:Length of Stay; D008875:Middle Aged; D011446:Prospective Studies; D029424:Pulmonary Disease, Chronic Obstructive / Q000145:classification / Q000150:complications / Q000628:therapy*; D011782:Quadriplegia / Q000139:chemically induced* / Q000209:etiology / Q000473:pathology; D012121:Respiration, Artificial / Q000009:adverse effects*; D012307:Risk Factors; D018805:Sepsis / Q000150:complications
chemical_list: D000305:Adrenal Cortex Hormones